News | Artificial Intelligence | June 30, 2020

DiA Granted FDA Approvals for New COVID-19-related AI Solutions

DiA’s new AI-based LVivo RV enables rapid assessment of right ventricle dysfunction in COVID-19 patients, while LVivo Bladder supports clinicians with automated bladder volume analysis to minimize scan time and risk of infection

DiA’s new AI-based LVivo RV enables rapid assessment of right ventricle dysfunction in COVID-19 patients, while LVivo Bladder supports clinicians with automated bladder volume analysis to minimize scan time and risk of infection

June 30, 2020 — DiA Imaging Analysis, a leading provider of advanced AI-based solutions for ultrasound analysis, announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) 510(k) and a European CE mark for two additional AI-powered ultrasound analysis solutions.

  • LVivo RV is the first AI-based fully automated analysis of the heart’s right ventricle (RV) and can be used to diagnose and monitor right heart ailments in acute and chronic patients suspected to have RV injury, including those with COVID-19.
  • LVivo Bladder uses AI to deliver automated bladder volume measurements on ultrasound devices, significantly reducing patient scanning time and risk of infection.

Both solutions join DiA’s LVivo Toolbox, of now six FDA/CE-cleared AI-powered ultrasound solutions in total. The company was recently awarded a COVID-19-specific government grant from Israel’s Innovation Authority to accelerate access to its AI-based offerings in response to the COVID-19 pandemic.

“Physicians now face a host of new challenges and restrictions on the frontlines that underscores the critical role of ultrasound and value of having access to AI-powered solutions,” said Hila Goldman-Aslan, DiA’s CEO and Co-Founder. “With today’s FDA and CE approvals, DiA takes a big step toward strengthening our AI offerings for cardiac ultrasound while realizing our vision of making ultrasound analysis smarter and more accessible across a broader range of healthcare segments.”

There is growing evidence linking COVID-19 mortality and right ventricle heart failure. A study at Mount Sinai Morningside Hospital found that 31% of the patients hospitalized with COVID-19 had right ventricle failure, and that 41% of patients in this subset who died had signs of RV dilation or enlargement. By automatically providing quantified 2D analysis of the RV’s size and function, LVivo RV helps detect and monitor right heart failure. LVivo RV utilizes DiA’s flagship LVivo Artificial Intelligence platform to deliver faster, more accurate analysis while at the same time enabling clinicians to shorten patient scanning and evaluation time.

“The RV has always been very difficult to evaluate, due to its unique structure and location,” said Anthony M. Demaria, M.D., a leading cardiologist at University of California, San Diego (UCSD) Medical Center and a co-investigator of the multi-center study for LVivo RV. “This is further compounded by the complexity of the analysis itself, which relies on a combination of manual calculations and visual user input. LVivo RV is a welcome and very useful addition to clinicians’ toolbox for more quickly and effectively monitoring the right ventricle.”

Additional co-investigators of the study included David Rosenmann, M.D., and Shemi Carasso, M.D., at Israel’s Shaare Zedek Medical Center and Baruch Padeh Medical Center, respectively.

With LVivo Bladder, DiA extends its expertise beyond cardiology to abdominal ultrasound. Healthcare-associated urinary tract infections (UTIs) account for up to 40% of infections in hospitals and 23% of infections in the intensive care unit (ICU). LVivo Bladder enables ultrasound users to automatically and accurately measure bladder volume, which is currently done on cart-based systems manually or by dedicated bladder scanners. LVivo Bladder’s automated volume calculation turns any ultrasound device into a bladder scanner, minimizing patient scanning time and helping to prevent unnecessary catheterization to reduce the risk of infection.

For more information: www.dia-analysis.com

Related Content

Of all the buzzwords one would have guessed would dominate 2020, few expected it to be “virtual”. We have been virtualizing various aspects of our lives for many years, but the circumstances of this one has moved almost all of our lives into the virtual realm.

Getty Images

Feature | Radiology Education | September 18, 2020 | By Jef Williams
Of all the buzzwords one would have guessed would dominate 2020, few expected it to be “virtual”.
The COVID-19 pandemic has impacted every facet of personal life, business operations and healthcare, including breast imaging and breast cancer care.

Getty Images

Feature | Breast Imaging | September 18, 2020 | By Susan Harvey, M.D.
The COVID-19 pandemic has impacted every facet o
As the silos of data and diagnostic imaging PACS systems are being collapsed and secured, the modular enterprise imaging platform approach is gaining significance, offering systemness and security
Feature | Coronavirus (COVID-19) | September 18, 2020 | By Anjum M. Ahmed, M.D., MBBS, MBA, MIS
COVID-19 is now everywhere, and these are the lo
Cloud and cloud-native architecture is the future for computing solutions in EI applications

Getty Images

Feature | Enterprise Imaging | September 18, 2020 | By Henri “Rik” Premo
With over five years of presence in the rapidly expanding...
Figure 1. Doppler flows in subpleural consolidation shows smoothly dilated branching arteries

Figure 1. Doppler flows in subpleural consolidation shows smoothly dilated branching arteries 

Feature | Radiology Imaging | September 17, 2020 | By Robert Bard, M.D. PC, DABR, FASLM
COVID-19 is routinely studied using...
Ultrasound-guided carpal tunnel release quickly improves hand function and reduces hand discomfort, making the procedure a safe, effective, and less invasive alternative to traditional open or endoscopic surgery

Patients answered three questionnaires (Quick-Disabilities of the Arm, Shoulder, and Hand [QDASH] and two parts of the Boston Carpal Tunnel Syndrome Questionnaire: symptom severity [BCTSQ-SS] and functional status [BCTSQ-FS] scales) assessing the affected wrist's function and discomfort immediately pre-procedure, 2 weeks post-procedure, and at least one year post-procedure. Infographic courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Ultrasound Imaging | September 17, 2020
September 17, 2020 — According to ARRS' American Journal of Roentgenology (AJR),...
Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
News | Artificial Intelligence | September 16, 2020
September 16, 2020 — Konica Minolta Healthcare Americas, Inc.
Feature | Coronavirus (COVID-19) | September 15, 2020
September 15, 2020 — The world is facing a global pandemic with unknown implications, but it is now well known ...